Literature DB >> 30698688

Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti.

Kathleen F Walsh1, Stalz Charles Vilbrun2, Ariadne Souroutzidis3, Sobieskye Delva2, Guy Joissaint2, Laurent Mathurin2, Oksana Ocheretina1, Pierre Cremieux3, Jean William Pape2, Serena P Koenig4.   

Abstract

We report outcomes for a cohort of patients with multidrug-resistant tuberculosis who received high-dose isoniazid in Haiti. Patients who received high-dose isoniazid had a faster time to culture conversion and higher odds of successful outcome, despite high-level isoniazid resistance. This suggests high-dose isoniazid may have effectiveness even with phenotypic resistance.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  MDR-TB; drug resistance; high-dose isoniazid; tuberculosis

Mesh：

Substances：

Year:  2019        PMID： 30698688      PMCID： PMC7322692          DOI： 10.1093/cid/ciz039

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  7 in total

1.  Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

2.  Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping.

Authors:  Burkhard Springer; Romana C Calligaris-Maibach; Claudia Ritter; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2008-10-15       Impact factor: 5.948

Review 3.  Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.

Authors:  Kelly E Dooley; Carole D Mitnick; Mary Ann DeGroote; Ekwaro Obuku; Vera Belitsky; Carol D Hamilton; Mamodikoe Makhene; Sarita Shah; James C M Brust; Nadza Durakovic; Eric Nuermberger
Journal:  Clin Infect Dis       Date:  2012-05-21       Impact factor: 9.079

4.  Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa.

Authors:  Karen R Jacobson; Danie Theron; Thomas C Victor; Elizabeth M Streicher; Robin M Warren; Megan B Murray
Journal:  Clin Infect Dis       Date:  2011-08       Impact factor: 9.079

5.  Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis.

Authors:  Hans L Rieder; Armand Van Deun
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

6.  A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis.

Authors:  S K Katiyar; S Bihari; S Prakash; M Mamtani; H Kulkarni
Journal:  Int J Tuberc Lung Dis       Date:  2008-02       Impact factor: 2.373

7.  Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.

Authors:  Marlanka A Zuur; Jotam G Pasipanodya; Dick van Soolingen; Tjip S van der Werf; Tawanda Gumbo; Jan-Willem C Alffenaar
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079
  7 in total
  9 in total

1.  Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations.

Authors:  Sean Wasserman; Jennifer Furin
Journal:  Am J Respir Crit Care Med       Date:  2020-06-01       Impact factor: 21.405

2.  Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries.

Authors:  Valérie Schwœbel; Arnaud Trébucq; Zacharie Kashongwe; Alimata S Bakayoko; Christopher Kuaban; Juergen Noeske; Souleymane H Harouna; Mahamadou B Souleymane; Alberto Piubello; François Ciza; Valentin Fikouma; Michel Gasana; Martial Ouedraogo; Martin Gninafon; Armand Van Deun; Elisa Tagliani; Daniela M Cirillo; Kobto G Koura; Hans L Rieder
Journal:  EClinicalMedicine       Date:  2020-02-10

3.  Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen.

Authors:  Pauline Lempens; Tom Decroo; Kya J M Aung; Mohammad A Hossain; Leen Rigouts; Conor J Meehan; Armand Van Deun; Bouke C de Jong
Journal:  Int J Infect Dis       Date:  2020-08-20       Impact factor: 3.623

4.  Drug-resistant TB prevalence study in 5 health institutions in Haiti.

Authors:  Jonathan Hoffmann; Carole Chedid; Oksana Ocheretina; Chloé Masetti; Patrice Joseph; Marie-Marcelle Mabou; Jean Edouard Mathon; Elie Maxime Francois; Juliane Gebelin; François-Xavier Babin; Laurent Raskine; Jean William Pape
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

5.  Genome-wide association studies of global Mycobacterium tuberculosis resistance to 13 antimicrobials in 10,228 genomes identify new resistance mechanisms.

Authors: 
Journal:  PLoS Biol       Date:  2022-08-09       Impact factor: 9.593

6.  Time to Culture Conversion of Bedaquiline and High-Dose Isoniazid for Drug-Resistant Tuberculosis.

Authors:  Kathleen F Walsh; Stalz Charles Vilbrun; Ariadne Souroutzidis; Joshua Ellis; Sobiesyke Delva; Guy Joissaint; Kathryn M Dupnik; Patrice Joseph; Jean W Pape; Serena P Koenig
Journal:  Open Forum Infect Dis       Date:  2022-08-29       Impact factor: 4.423

7.  Population Pharmacokinetics and Significant Under-Dosing of Anti-Tuberculosis Medications in People with HIV and Critical Illness.

Authors:  Prakruti S Rao; Christopher C Moore; Amir A Mbonde; Edwin Nuwagira; Patrick Orikiriza; Dan Nyehangane; Mohammad H Al-Shaer; Charles A Peloquin; Jean Gratz; Suporn Pholwat; Rinah Arinaitwe; Yap Boum; Juliet Mwanga-Amumpaire; Eric R Houpt; Leonid Kagan; Scott K Heysell; Conrad Muzoora
Journal:  Antibiotics (Basel)       Date:  2021-06-18

8.  Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.

Authors:  Kelly E Dooley; Sachiko Miyahara; Florian von Groote-Bidlingmaier; Xin Sun; Richard Hafner; Susan L Rosenkranz; Elisa H Ignatius; Eric L Nuermberger; Laura Moran; Kathleen Donahue; Susan Swindells; Naadira Vanker; Andreas H Diacon
Journal:  Am J Respir Crit Care Med       Date:  2020-06-15       Impact factor: 21.405

Review 9.  Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence.

Authors:  Arnaud Trébucq; Tom Decroo; Armand Van Deun; Alberto Piubello; Chen-Yuan Chiang; Kobto G Koura; Valérie Schwoebel
Journal:  J Clin Med       Date:  2019-12-25       Impact factor: 4.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.